LifeStyle
-
Arthrex selected as new U.S. partner to sell Hanmi's arthritis treatment hyalrheuma
SEOUL -- Hanmi Pharmaceutical, a major drugmaker in South Korea, has selected Arthrex, an American medical device company, as a new partner to sell its arthritis treatment, hyalrheuma, in the United States. Hyalrheuma is a polymer hyaluronic acid injection developed with fermentation technology. It is directly administered to joints. Arthrex is in charge of marketing and sales, while Hanmi supplies finished products. Hanmi said hyalrheuma would be sold under the brand name "Syn
7 March 2022
-
Hanmi partners with domestic company to promote exports of saliva-based rapid antigen kits
SEOUL -- Hanmi Pharmaceutical, a major drugmaker in South Korea, has partnered with PHC, a domestic bio company that focuses on in vitro diagnosis and digital healthcare business, to promote exports of COVID-19 self-testing kits, including a rapid antigen kit that use saliva as samples to acquire rapid results. Hanmi is in charge of product planning, sales, marketing, and local licensing for a neutralizing antibody kit using blood samples and two rapid antigen kits based on a naso
4 March 2022
-
KT unveils electric wheekchairs attached with AI and automatic call functions at MWC
BARCELONA -- Electric wheelchairs that enhanced user convenience and safety functions with artificial intelligence and internet of things (IoT) technologies were unveiled by South Korea's major telecom company, KT, at MWC, a mobile device exhibition in Barcelona, Spain. They can automatically make emergency calls for help by recognizing collisions and abnormal situations. In collaboration with Hycore, a domestic robot system developer, KT has developed two types of motorized
2 March 2022
-
Researchers use whale genes and protein structures to develop new drug substance for NAFLD
SEOUL -- South Korean researchers have used whale genes and protein structures to develop a new drug candidate substance that can treat non-alcoholic fatty liver disease (NAFLD), an umbrella term for a range of conditions caused by a build-up of fat in the liver. Related technology has been transferred to a private company for commercialization. NAFLD is usually seen in people who are overweight or obese. Early-stage NAFLD does not usually cause any harm, but it can lead to serious
23 February 2022
-
Samsung's Galaxy S22 components use polyamide resins containing recycled fishing nets
SEOUL -- In an effort to help reduce ocean pollution by plastic waste, Samsung Electronics, a leading smartphone maker in the world, has incorporated upcycled polyamide resins into key bracket components of its new Galaxy S22 series and the inner cover of the S Pen. Samsung said it has partnered with Royal DSM, a Dutch company active in the fields of health, nutrition and materials, to gather waste fishing nets along the coastlines of the Indian Ocean. Collected fishing nets were cl
16 February 2022
-
GI Cell sets new record in culturing highly active natural killer cells
SEOUL -- GI Cell, a South Korean developer of immune cell therapy products, claimed to have set a new world record in culturing highly active natural killer cells with 200 liters. Natural killer (NK) cells are a type of white blood cell and are seen as a promising tool for use in adoptive immunotherapy because they efficiently attack cancer cells or cells infected with viruses or bacteria. Because NK cells are the most powerful immune cells in the human body and are extremely safe
16 February 2022
-
Researchers develop antibacterial, antiviral additive capable of generating high metal ions
SEOUL -- A government-funded research body in South Korea has developed a functional antibacterial and antiviral additive that can be widely applied to display films, functional fibers, home appliance films, window films, car interior and exterior materials, and sanitary products. If it is mixed with resin, the antibacterial effect is semi-permanent. The colorless, transparent additive that generates high metal ions was developed through a formulation process by mixing several met
3 February 2022
-
Researchers present safe and efficient approach for sustainable hemophilia therapy
SEOUL -- Hemophilia is an incurable hereditary disease. Although innovative treatments such as gene therapy or bispecific antibody therapy have been introduced, a fundamental treatment has not yet been developed, and hemophilia A and B are among the most prominent targets for gene therapy. South Korean researchers have presented a safe and efficient approach for the sustainable treatment of hemophilia. Unlike conventional hemophilia treatment that directly fills insufficient coagula
24 January 2022
